

## **REMARKS**

### **Status of the Claims**

After entry of this amendment, claims 13-14 and 19 are pending. Claims 15-18 and 20 have been canceled without prejudice to future prosecution. Claims 1-12 and 21-29 were previously canceled. Claim 13 has been amended to incorporate elements of claims 15-18. Claims 13 and 19 have been amended to delete the recitation "variant thereof." Thus, no new matter is added by these amendments.

### **Rejection Under 35 U.S.C. § 112, First Paragraph**

Claims 13-20 are rejected under 35 U.S.C. § 112, first paragraph as allegedly lacking adequate written description. The claims have been amended. To the extent the rejection applies to the amended claims, Applicants respectfully traverse.

In making the rejection, the Examiner acknowledges that the specification adequately describes STC-1 inhibition of HGF-induced cell migration, but not bFGF- or VEGF-induced cell migration (*see*, Office Action at page 3, last paragraph bridging to page 4). Solely to expedite prosecution, the claims have been amended to recite that the angiogenic process is inhibited is cell migration.

The Examiner also continues to allege that the specification does not enable variants of STC-1. Applicants do not agree, but solely in the interest of expediting prosecution, the claims have been amended to delete the recitation "variants thereof."

Accordingly, Applicants respectfully request withdrawal of this rejection under 35 U.S.C. § 112, first paragraph.

**SUMMARY**

In view of the foregoing, Applicants respectfully request that a timely Notice of Allowance be issued in this case.

If the Examiner believes that a telephone conference would expedite the prosecution of the subject application, the Examiner is strongly encouraged to call the undersigned at the number indicated below.

In the unlikely event that this document is separated from the transmittal letter or if fees are required, applicants petition the Commissioner to authorize charging our Deposit Account 07-0630 for any fees required or credits due and any extensions of time necessary to maintain the pendency of this application.

Respectfully submitted,  
GENENTECH, INC.

Date: March 4, 2008

By: 

Carol A. Fang  
Reg. No. 48,631  
Telephone No. (650) 467-2901